Barrett Hodgson Pakistan (Pvt.) Ltd
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer with a broad branded portfolio and partnerships with international healthcare companies.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Barrett Hodgson Pakistan (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- F/423, S.I.T.E., Karachi-75700, Pakistan · 75700
- Website
- barretthodgson.com ↗
- Phone
- +92 21 32570651-57
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Barrett Hodgson Pakistan (Pvt.) Ltd is priced against the market
165 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Adgam Eye | Latanoprost | 0.05 mg/mL | Ophthalmic drops | 2.5 ml | 045472 | PKR 577.76 | PKR 231.10/mL | 🔒 Pharma Pro |
| Adgam-T | Latanoprost + Timolol | 0.05 mg/mL + 5 mg/mL | Eye drops | 2.5 ml | 045473 | PKR 1,501.53 | PKR 600.61/mL | No comparator |
| Ampress | Amlodipine | 10 mg | Tablet | 20's | 024266 | PKR 538.89 | PKR 26.94/tablet | 🔒 Pharma Pro |
| Ampress | Amlodipine | 5 mg | Tablet | 20's | 024365 | PKR 275.49 | PKR 13.77/tablet | 🔒 Pharma Pro |
| Bar-D | Cholecalciferol | 5 mg/mL (200,000 IU/mL) | Injection | 1's | 083222 | PKR 218.03 | PKR 218.03/vial/unit | 🔒 Pharma Pro |
| Barforte | Prednisolone | 10 mg/mL | Suspension | 5ml | 008629 | PKR 150.77 | PKR 30.15/mL | 🔒 Pharma Pro |
| Barigyl | Metronidazole | 200 mg | Tablet | 200's | 095998 | PKR 353.74 | PKR 1.77/tablet | 🔒 Pharma Pro |
| Barigyl | Metronidazole | 400 mg | Tablet | 200's | 095999 | PKR 626.51 | PKR 3.13/tablet | 🔒 Pharma Pro |
| Barigyl | Metronidazole (Benzoate) | 200 mg/5 mL | Suspension | 90ml | 096000 | PKR 87.20 | PKR 0.97/mL | 🔒 Pharma Pro |
| Barigyl | Metronidazole | 500 mg/100 mL | IV infusion | 100ml | 108742 | PKR 110.19 | PKR 1.10/mL | 🔒 Pharma Pro |
| Barilol | Bisoprolol fumarate | 2.5 mg | Tablet | 14's | 075859 | PKR 73.05 | PKR 5.22/tablet | 🔒 Pharma Pro |
| Barilol | Bisoprolol fumarate | 5 mg | Tablet | 20's | 075860 | PKR 286.75 | PKR 14.34/tablet | 🔒 Pharma Pro |
| Barilol | Bisoprolol fumarate | 10 mg | Tablet | 20's | 075861 | PKR 512.87 | PKR 25.64/tablet | 🔒 Pharma Pro |
| Barilol-H | Bisoprolol + Hydrochlorothiazide | 2.5 mg + 6.25 mg | Tablet | 14's | 086714 | PKR 95.18 | PKR 6.80/tablet | 🔒 Pharma Pro |
| Barilol-H | Bisoprolol + Hydrochlorothiazide | 2.5 mg + 6.25 mg | Tablet | 10's | 086714 | PKR 68.22 | PKR 6.82/tablet | 🔒 Pharma Pro |
| Barilol-H | Bisoprolol + Hydrochlorothiazide | 5 mg + 6.25 mg | Tablet | 14's | 086715 | PKR 150.71 | PKR 10.77/tablet | 🔒 Pharma Pro |
| Barilol-H | Bisoprolol + Hydrochlorothiazide | 10 mg + 6.25 mg | Tablet | 20's | 086716 | PKR 356.94 | PKR 17.85/tablet | 🔒 Pharma Pro |
| Barimox | Moxifloxacin | 400 mg | Tablet | 5's | 061443 | PKR 994.59 | PKR 198.92/tablet | 🔒 Pharma Pro |
| Baripenem | Meropenem | 500 mg | Injection | 1's | 095252 | PKR 1,806.40 | PKR 1,806.40/vial/unit | 🔒 Pharma Pro |
| Baripenem | Meropenem | 1 g | Injection | 1's | 095253 | PKR 3,447.18 | PKR 3,447.18/vial/unit | 🔒 Pharma Pro |
| Barizold | Linezolid | 600 mg | Tablet | 12's | 076341 | PKR 5,351.96 | PKR 446.00/tablet | 🔒 Pharma Pro |
| Barizold | Linezolid | 400 mg | Tablet | 12's | 076342 | PKR 3,057.06 | PKR 254.76/tablet | 🔒 Pharma Pro |
| Barizold | Linezolid | 100 mg/5 mL | Dry suspension | 60 ml | 076343 | PKR 712.13 | PKR 11.87/mL | 🔒 Pharma Pro |
| Barizold | Linezolid | 200 mg/100 mL | IV infusion | 100 ml | 076478 | PKR 724.48 | PKR 7.24/mL | 🔒 Pharma Pro |
| Barizold | Linezolid | 600 mg/300 mL | IV infusion | 300 ml | 080288 | PKR 1,231.67 | PKR 4.11/mL | 🔒 Pharma Pro |
| Barizold | Linezolid | 400 mg/200 mL | IV infusion | 200 ml | 080289 | PKR 1,026.39 | PKR 5.13/mL | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 750 mg | Tablet | 30's | 094919 | PKR 2,896.70 | PKR 96.56/tablet | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 750 mg | Tablet | 10's | 094919 | PKR 965.57 | PKR 96.56/tablet | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 1000 mg | Tablet | 30's | 094920 | PKR 3,620.87 | PKR 120.70/tablet | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 1000 mg | Tablet | 10's | 094920 | PKR 1,206.96 | PKR 120.70/tablet | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 500 mg | Tablet | 10's | 094921 | PKR 855.06 | PKR 85.51/tablet | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 250 mg | Tablet | 10's | 094922 | PKR 515.00 | PKR 51.50/tablet | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 100 mg/mL | Oral solution | 60ml | 094923 | PKR 707.64 | PKR 11.79/mL | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 500 mg | Extended-release tablet | 10's | 096001 | PKR 939.58 | PKR 93.96/tablet | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 500 mg/5 mL | Injection | 5ml x 10's | 108740 | PKR 6,891.86 | PKR 137.84/mL | 🔒 Pharma Pro |
| Barlev | Levetiracetam | 500 mg/5 mL | Injection | 5ml x 1's | 108740 | PKR 689.18 | PKR 137.84/mL | 🔒 Pharma Pro |
| Barotrop 18mcg DPI | Tiotropium | 18 mcg | Capsule | 6's | 086691 | PKR 150.07 | PKR 25.01/capsule | 🔒 Pharma Pro |
| Barotrop 18mcg DPI | Tiotropium | 18 mcg | Capsule | 15's | 086691 | PKR 367.68 | PKR 24.51/capsule | 🔒 Pharma Pro |
| Barotrop 18mcg DPI | Tiotropium | 18 mcg | Capsule | 2x10's | 086691 | PKR 480.23 | PKR 24.01/capsule | 🔒 Pharma Pro |
| Barotrop 18mcg DPI | Tiotropium | 18 mcg | Capsule | 3x10's | 086691 | PKR 720.34 | PKR 24.01/capsule | 🔒 Pharma Pro |
| Barresten | Clotrimazole | 500 mg | Vaginal tablet | 1's | 081446 | PKR 130.32 | PKR 130.32/tablet | 🔒 Pharma Pro |
| Barresten | Clotrimazole | 1% | Cream | 15gm | 086692 | PKR 69.03 | PKR 4.60/g | 🔒 Pharma Pro |
| Barresten | Clotrimazole | 2% | Cream | 35gm | 086693 | PKR 105.05 | PKR 3.00/g | 🔒 Pharma Pro |
| Barresten | Clotrimazole | 100 mg/g (10%) | Vaginal cream | 5gm | 086694 | PKR 139.71 | PKR 27.94/g | 🔒 Pharma Pro |
| Barresten HC | Clotrimazole + Hydrocortisone | 1% + 1% w/w | Cream | 10 g | 117945 | PKR 118.09 | PKR 11.81/g | 🔒 Pharma Pro |
| Barresten HC | Clotrimazole + Hydrocortisone | 10 mg/g + 10 mg/g | Cream | 30 g | 117945 | PKR 324.74 | PKR 10.82/g | 🔒 Pharma Pro |
| Britanyl Terbutaline | Terbutaline | 0.5 mg/mL | Injection | 5’s amp | 044256 | PKR 125.32 | PKR 25.06/vial/unit | No comparator |
| Budecort-F | Budesonide + Formoterol | 200 mcg + 6 mcg | Inhalation capsule | 30's | 085999 | PKR 412.69 | PKR 13.76/capsule | 🔒 Pharma Pro |
| Budecort-F | Budesonide + Formoterol | 100 mcg + 6 mcg | Inhalation capsule | 30's | 086000 | PKR 295.63 | PKR 9.85/capsule | 🔒 Pharma Pro |
| Cefamezin | Cefazolin | 250 mg | IV/IM injection | 1's | 008126 | PKR 113.87 | PKR 113.87/vial/unit | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.